CDMO Utilization and Contract Value: Three Conditions for Revenue Conversion
Biopharmaceutical CDMO bioreactor capacity does not translate directly into revenue. Examine technology transfer, batch schedules, product mix, and contract scope to interpret utilization and backlog.
CDMO revenue depends on customer-specific technology transfer and production schedules, successful batches, and acceptance terms as well as facility capacity. Even with rising contract value and factory utilization, differences in execution timing and product mix can change quarterly revenue and margins.
Capacity in liters does not fully explain production revenue
Even with the same bioreactor capacity, the number of batches that can be supplied varies with product-specific production times, cell productivity, changeovers, and cleaning. The value of output also depends on the product and contract, so multiplying facility liters by an industry-average price to establish revenue can produce substantial errors. Samsung Biologics' 2025 results announcement discusses both factory operations and expanded project execution. Use this to look beyond the size of expansion to which factories customer projects will enter, when they will enter, and how they reach stable commercial production.
Separate capacity reservations, technology transfer, and production in contracts
CDMO contracts may include development support, technology transfer, capacity reservations, and commercial manufacturing. If specific consideration and performance obligations are undisclosed, do not simply divide contract value by contract years to estimate annual revenue. Delays in a customer's clinical trials or drug approval can change production volumes, while minimum purchase and cancellation terms also matter. Check whether changes in disclosed contract value reflect higher volumes, longer duration, exchange rates, or revised terms. It is also important not to double-count new contracts and increases to existing contracts as order growth.
Utilization, revenue recognition, and cash collection move separately
Equipment used for technology transfer or validation batches may be occupied without generating the same returns as commercial production. Check whether the company's utilization figure means capacity reservation or actual equipment use. Quarterly results can fluctuate substantially when batch completion and deliveries are concentrated in particular periods. Reading audited revenue recognition policies alongside contract assets, contract liabilities, and cash flows helps distinguish these effects. New factories may incur depreciation and operating expenses first, so do not directly apply high long-term contracted capacity coverage to current margins.
Worked example
Hypothetical example: A factory has available annual operating time equivalent to 100 batches and produces 70 batches, giving a simple batch-based utilization rate of 70%. If 10 are technology transfer or validation batches and 60 are commercial batches, you cannot apply a commercial batch price to all 70. Assuming contractual consideration of KRW 500 million for each of the 60 commercial batches and full recognition in the current period, the related revenue is KRW 30 billion. Development and reservation fees are calculated separately.
What to check
- Have you checked whether utilization means reservations or actual production use?
- Have you separated technology transfer, validation, and commercial batches?
- Have you avoided double-counting contract increases and new contracts?
- Have you considered batch recognition timing alongside new factory costs?
Sources and primary materials
This is educational material about research methods. For an actual company decision, verify the filings and primary sources for the relevant period.